SCHEMBL13789405

SCHEMBL13789405

Fc1cc(F)c(-c2nc(Cl)c3sccc3n2)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 1/20 0.41
▸ MKNK1 Q9BUB5 1/20 0.41
▸ MKNK2 Q9HBH9 1/20 0.41
▸ CSNK2A1 P68400 6/20 0.36
▸ MAPT P10636 3/20 0.35
▸ NPC1 O15118 4/20 0.35
▸ RAB9A P51151 4/20 0.35
▸ NPSR1 Q6W5P4 4/20 0.35
▸ CTDSP1 Q9GZU7 3/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ GLA P06280 1/20 0.35
▸ ADORA2A P29274 3/20 0.35
▸ ADORA1 P30542 2/20 0.35
▸ ATM Q13315 1/20 0.34
▸ PRKCI P41743 1/20 0.34
▸ PDE4B Q07343 2/20 0.33
▸ PDE4A P27815 1/20 0.33
▸ PDE4C Q08493 1/20 0.33
▸ PDE4D Q08499 1/20 0.33
▸ PDE7A Q13946 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13789329 0.86 AXL (0.42) AXLMKNK1MKNK2MAPTNPC1
SCHEMBL14103743 0.82 PRKCI (0.40) AXLMKNK1MKNK2CSNK2A1MAPT
SCHEMBL13789442 0.79 AXL (0.39) AXLMKNK1MKNK2CSNK2A1MAPT
SCHEMBL13789440 0.78 AXL (0.41) AXLMKNK1MKNK2MAPTNPC1
SCHEMBL13789438 0.78 AXL (0.41) AXLMKNK1MKNK2CSNK2A1MAPT
SCHEMBL13789312 0.78 AXL (0.41) AXLMKNK1MKNK2MAPTNPC1
SCHEMBL13789316 0.78 MAPT (0.50) AXLMKNK1MKNK2MAPTNPC1
SCHEMBL14104146 0.77 AXL (0.40) AXLMKNK1MKNK2CSNK2A1MAPT
SCHEMBL4518564 0.76 AXL (0.39) AXLMKNK1MKNK2CSNK2A1MAPT
SCHEMBL13789321 0.76 AXL (0.39) AXLMKNK1MKNK2CSNK2A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7557112-B2 Aromatic-ring-fused pyrimidine derivative ASTELLAS PHARMA INC. (JP) 2009-07-07 — — US disclosed
US-7557112-B2 Aromatic-ring-fused pyrimidine derivative ASTELLAS PHARMA INC. (JP) 2009-07-07 — — US disclosed
US-20070249587-A1 Aromatic-Ring-Fused Pyrimidine Derivative ASTELLAS PHARMA INC. (JP) 2007-10-25 — — US disclosed
US-20070249587-A1 Aromatic-Ring-Fused Pyrimidine Derivative ASTELLAS PHARMA INC. (JP) 2007-10-25 — — US disclosed
EP-1806347-A1 AROMATIC-RING-FUSED PYRIMIDINE DERIVATIVE Astellas Pharma Inc. (JP) 2007-07-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249587-A1 Aromatic-Ring-Fused Pyrimidine Derivative GPR119, NOD1, IRS1 AXL 425/4885MKNK1 672/4885MKNK2 781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback